Citations

Showing 10 of 108104 citations.

Lymphatic Mapping Using US Microbubbles before Lymphaticovenous Anastomosis Surgery for Lymphedema
Jang, Samuel , Lee, Christine U. , Hesley, Gina K. , Knudsen, John M. , Brinkman, Nathan , Tran, Nho V. , Hesley, Gina , Brinkman, Nathan J

Mayo Clinic

Radiology | April 5, 2022 | Volume: 304 | Issue: 1 | Pages: 218-224

10.1148/radiol.212351 | PMID 35380494 Get It

Tackling the Minority Tax: A Roadmap to Redistributing Engagement in Diversity, Equity, and Inclusion Initiatives
Faucett, Erynne A. , Brenner, Michael , Thompson, Dana M. , Flanary, Valerie A.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 5, 2022 | Volume: 166 | Issue: 6 | Pages: 1174-1181

10.1177/01945998221091696 | PMID 35380882 Get It

Academic medical centers striving to implement diversity, equity, and inclusion (DEI) and antiracism initiatives often ask faculty to volunteer substantial time to committee work, recruitment, mentoring, community, and administrative responsibilities. These requests are not in lieu of current workload and seldom count toward scholarship; the service may go unrecognized, unrewarded, and uncompensated. URiM faculty (underrepresented in medicine) providing such service thus pay a minority tax when precious time is syphoned away from career‐advancing activities and personal growth. The resulting strain on available resources has social, psychological, and monetary ramifications that can undermine the long‐term objectives of DEI initiatives. We examine the facets of the minority tax, consider the current state of diversity, and present a roadmap to redistribute, reform, and reduce URiM taxation through shared engagement in DEI initiatives. Key interventions include ascribing value to DEI efforts, implementing evidence‐based policies to reduce bias, and promoting mentorship, sponsorship, and allyship.
Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomes—protocol for a population-based retrospective study
Farquhar, Hamish , Edwards, Adrienne L. , Matteson, Eric L. , Thiessen, Rennae, Ganly, Edward, Beckert, Lutz , Stamp, Lisa K.

Mayo Clinic

BMJ Open | April 5, 2022 | Volume: 12 | Issue: 4 | Pages: e050934

10.1136/bmjopen-2021-050934 | PMID 35383056 Get It

Introduction Rheumatoid arthritis (RA) affects approximately 0.5%–1% of the general population. Clinically significant interstitial lung diseases (ILD) develops in just under 10% of people with RA, and subclinical disease is more common. Little is known about RA-ILD in New Zealand (NZ), or the number of persons with RA in Canterbury, NZ. This study aims to determine: (1) incidence and prevalence of RA, (2) incidence and prevalence of RA-ILD, (3) clinical characteristics and risk factors for the development of RA-ILD, (4) long-term outcomes of RA-ILD, in the population resident within the Canterbury District Health Board (CDHB) catchment area. Methods and analysis Persons aged 18 years of age and older, and resident in the region covered by the CDHB with RA as well as RA-ILD will be identified by retrospective review of medical records. Prevalent as well as incident cases of RA between 1 January 2006 and 31 December 2008 and between 1 January 2011 and 31 December 2013 will be identified, and followed until 30 June 2019. Existing as well as incident cases of RA-ILD during this time will be identified. The association between the development of ILD and clinical characteristics and environmental exposures will be examined using Cox-proportional hazard models. Kaplan-Meier methods will be used to estimate survival rates for patients with RA-ILD. Mortality for people with RA and RA-ILD will also be compared with the general population of the CDHB. Ethics and dissemination Data will be obtained by retrospective review of medical records. Deidentified patient data will be stored in a secure online database. Data on individual patients will not be released, and all results will only be published in aggregate. Ethical approval has been obtained from the University of Otago Human Research Ethics Committee (REF HD18/079). Results will be published in peer-reviewed medical journals and presented at conferences. Trial registration number ACTRN12619001310156; Pre-results.
Neuropilin-1 deficiency in vascular smooth muscle cells is associated with hereditary hemorrhagic telangiectasia arteriovenous malformations
Kilari, Sreenivasulu , Wang, Ying , Singh, Avishek , Graham, Rondell P. , Iyer, Vivek , Thompson, Scott M. , Torbenson, Michael , Misra, Sanjay , Misra, Sanjay , Iyer, Vivek N , Graham, Rondell P , Torbenson, Michael S , Wang, Ying , Kilari, Sreenivasulu , Mukhopadhyay, Debabrata

Mayo Clinic

JCI Insight | April 5, 2022 | Volume: 7 | Issue: 9 | Pages: No page available

10.1172/jci.insight.155565 | PMID 35380991 Get It

Patients with hereditary hemorrhagic telangiectasia (HHT) have arteriovenous malformations (AVMs) with genetic mutations involving the activin-A receptor like type 1 ( ACVRL1 or ALK1 ) and endoglin ( ENG ). Recent studies have shown that Neuropilin-1 (NRP-1) inhibits ALK1. We investigated the expression of NRP-1 in livers of patients with HHT and found that there was a significant reduction in NRP-1 in perivascular smooth muscle cells (SMCs). We used Nrp1 SM22KO mice ( Nrp1 was ablated in SMCs) and found hemorrhage, increased immune cell infiltration with a decrease in SMCs, and pericyte lining in lungs and liver in adult mice. Histologic examination revealed lung arteriovenous fistulas (AVFs) with enlarged liver vessels. Evaluation of the retina vessels at P5 from Nrp1 SM22KO mice demonstrated dilated capillaries with a reduction of pericytes. In inflow artery of surgical AVFs from the Nrp1 SM22KO versus WT mice , there was a significant decrease in Tgfb1 , Eng , and Alk1 expression and phosphorylated SMAD1/5/8 (pSMAD1/5/8), with an increase in apoptosis. TGF-β1–stimulated aortic SMCs from Nrp1 SM22KO versus WT mice have decreased pSMAD1/5/8 and increased apoptosis. Coimmunoprecipitation experiments revealed that NRP-1 interacts with ALK1 and ENG in SMCs. In summary, NRP-1 deletion in SMCs leads to reduced ALK1, ENG, and pSMAD1/5/8 signaling and reduced cell death associated with AVM formation.
Transition of care of patients with eosinophilic gastrointestinal diseases: Challenges and opportunities
Hiremath, Girish , Chapa‐Rodríguez, Adrián, Katzka, David A. , Gold, Benjamin D., Dellon, Evan S. , Huang, Jeannie S. , Gupta, Sandeep K. , Spergel, Jonathan M. , Bredenoord, Albert J.

Mayo Clinic

Translational Science of Rare Diseases | April 5, 2022 | Volume: 6 | Issue: 1-2 | Pages: 13-23

10.3233/trd-220054 | PMID 35892038 Get It

Eosinophilic gastrointestinal disorders (EGID) are a group of allergen-mediated conditions which are characterized by eosinophilic inflammation affecting one or more parts of the gastrointestinal tract. A disproportionately higher number of EGID patients are diagnosed in the pediatric age group. Given the chronic course of EGIDs and lack of curative therapies at this time, majority of the pediatric EGID patients may require continued care well into their adulthood. However, to date, scant data are available regarding the health care transition (HCT), the transition of care (TC), and the effectiveness of transfer of care EGID patients from pediatric-oriented to adult-oriented providers. Herein, we review the lessons learnt from transfer of care of children with other chronic gastrointestinal and allergic conditions, analyze the current knowledge, potential barriers, the role of various stakeholders in successful transfer of care of EGID patients, propose a conceptual framework for HCT and TC of EGID patients, and identify outcome measures to ensure the quality of progression of care.
Prevalence of Cannabinoid (CBD) Use in Orthopaedic Sports Medicine Patients
Deckey, David G. , Tokish, John M. , Doan, Matthew, Bingham, Joshua S. , Doan, Matthew K. , Hassebrock, Jeffrey D. , Patel, Karan A. , Economopoulos, Kostas J. , Chhabra, Anikar

Mayo Clinic

Orthopaedic Journal of Sports Medicine | April 5, 2022 | Volume: 10 | Issue: 4 | Pages: No page available

10.1177/23259671221087629 | PMID 35400139 Get It

Background: Although there is some evidence that cannabinoid (CBD) products may provide a therapeutic effect for musculoskeletal pain, little is known about the usage patterns or their prevalence of use in orthopaedic sports medicine patients. Purpose: To report the prevalence and perceived self-efficacy of CBD products in patients evaluated in an orthopaedic sports medicine clinic. Study Design: Descriptive epidemiology study. Level of evidence, 2. Methods: The study population consisted of new patients who visited an orthopaedic surgery sports medicine clinic at a large academic center for consultation with a surgeon between August 2020 and March 2021. All patients were asked to complete a survey that assessed perceived pain and effectiveness of CBD products and other nonsurgical treatment modalities using the Single Assessment Numeric Evaluation score (range, 0-100) and the Numeric Pain Rating Scale (NRS). Descriptive factors were collected via chart review. Descriptive statistics were used to characterize the data. Results: Overall, 823 patients completed the survey (45.4% female; mean age, 51 years [range, 18-87 years]; mean body mass index, 28.9 [range, 17.2-58.4]). Body areas involved included 285 shoulders, 44 elbows, 76 hips, 276 knees, 58 ankles, and 77 other. Of these patients, 19% (152/823) endorsed the use of CBD products before their initial evaluation. The mean NRS for pain was significantly different between non-CBD users and CBD users (5.6 vs 6.1; P = .029). CBD users were significantly more likely to have tried other nonoperative modalities compared with nonusers, including nonsteroidal anti-inflammatory drugs (79.6% vs 69.8%; P = .032), bracing (44.7% vs 34.6%; P = .024), steroid injections (38.8% vs 21.6%; P < .001), and physical therapy (54% vs 36.1%; P < .001). In addition, 30.9% of CBD utilizers reported marijuana use compared with 2.8% of non-CBD users ( P < .001) for management of their pain. Conclusion: In the current study, 19% of patients had used CBD products to manage joint-related issues. Sports medicine providers should be aware of this high incidence of usage and the potential interactions CBD products may have with other treatment modalities. Further studies are needed to assess the effectiveness of CBD as a therapeutic agent and the specific interactions it has with other drugs and other forms of treatment.
Short Bowel Syndrome in Adults
Bering, Jamie , DiBaise, John K.

Mayo Clinic

American Journal of Gastroenterology | April 5, 2022 | Volume: 117 | Issue: 6 | Pages: 876-883

10.14309/ajg.0000000000001763 | PMID 35383576 Get It

Short bowel syndrome (SBS) is a rare disorder characterized by severe intestinal dysfunction leading to malabsorption of macronutrients and micronutrients that often results in permanent need of parenteral nutrition support. Patients can develop SBS because of massive intestinal resection or loss of intestinal function and consequently experience significant morbidity and increased healthcare utilization. The remaining anatomy and length of bowel after intestinal resection have important prognostic and therapeutic implications. Because patients with SBS constitute a heterogenous group, management is complex and multifaceted, involving nutrition support, fluid and electrolyte management, and pharmacologic therapies in particular to control diarrhea. Surgical interventions including intestinal transplantation may be considered in selected individuals. Successful care of these patients is best accomplished by a multidisciplinary team that is experienced in the management of this syndrome.
Level I PD‐MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia
Boel, Judith A., Bie, Rob M.A. de , Schmand, Ben , Dalrymple‐Alford, John C. , Adler, Charles H. , Goldman, Jennifer G. , Tröster, Alexander I. , Geurtsen, Gert J. , Disease, MDS Study Group Mild Cognitive Impairment in Parkinson's, Halliday, Glenda M. , Antonini, Angelo , Lewis, Simon J.G. , Biundo, Roberta , Segura, Bàrbara , Williams‐Gray, Caroline H. , de Bie, Rob M A , Adler, C H , Geurtsen, Gert J , Halliday, Glenda , Goldman, Jennifer G , Antonini, Angelo , Dalrymple-Alford, John C , Lewis, Simon J G , Williams-Gray, Caroline H , Segura, Barbara , Marras, Connie , Burn, David J. , Litvan, Irene , Disease, MDS Study Group Mild Cognitive Impairment in Parkinson's

Mayo Clinic

Movement Disorders Clinical Practice | April 5, 2022 | Volume: 9 | Issue: 4 | Pages: 479-483

10.1002/mdc3.13451 | PMID 35582313 Get It

ABSTRACTBackgroundThe criteria for PD‐MCI allow the use of global cognitive tests. Their predictive value for conversion from PD‐MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown.MethodsThe MDS PD‐MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD‐MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD.ResultsPD‐MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C‐statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II.ConclusionMMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD‐MCI.
Efficacy of empiric antibiotic therapy without aspiration for septic prepatellar bursitis in emergency department patients
Thomas, Alexa , Beyde, Adrian , Sandefur, Benjamin J. , Colbenson, Kristina M., Kisirwan, Imtithal, Finley, Anissa L., Krych, Aaron J. , Campbell, Ronna L. , Thomas, Alexa L , Campbell, Ronna L , Krych, Aaron J , Finley, Anissa , Mullan, Aidan F.

Mayo Clinic

Academic Emergency Medicine | April 5, 2022 | Volume: 29 | Issue: 8 | Pages: 1027-1032

10.1111/acem.14499 | PMID 35384127 Get It